Israel: Ha’aretz: The Health Ministry Is Violating The Priority Rights Of Pharmaceutical Companies

Last Updated: 18 August 2004
Article by Yafit Avital

The following is an article expressing the necessity in enacting Data Exclusivity Provisions in Israel. The Article is an interview with Adv. David Gilat and Adv. Eran Bareket published in Ha’aretz daily newspaper on December 21, 2003.

Attorneys David Gilat and Eran Bareket, who specialize in intellectual property, maintain that when, in the process of approving generic drugs, the Health Ministry uses product files submitted by manufacturers of proprietary medicinal products it violates the law as well as an international treaty that Israel has signed.

The generic drug industry has already spawned some of the most successful companies in Israel's business arena. Teva, whose market cap is $16 billion and is a leader of the global generic industry, is without doubt the most prominent example, but it is not the only one. Taro and Agis are growing, profitable companies that are considered leaders in their specific fields.

A generic drug is similar, although not necessarily identical, to the original drug, but produces the same biological effect as the original – at a much cheaper price. In a country where health costs continually rise and where the state's contribution constantly declines, the idea that a company should be allowed to produce generic drugs makes perfect sense. It is therefore hardly surprising that the concept of generic drugs is embraced by the public and by policymakers in Israel, and that no one questions this principle. Ostensibly, it is in everyone's best interest. Well, almost everybody's.

David Gilat, an attorney and patent attorney, disagrees. Gilat is a partner in Gilat, Bareket & Co., a law firm that specializes in intellectual property and represents proprietary drug manufacturers. In this field, their firm works hand in hand with Reinhold Cohn & Partners, one of the leading firms in Israel in the field of intellectual property.

Gilat thinks that the state has gone too far in its eagerness to promote the marketing of generic drugs, and even argues that the Ministry of Health is guilty of violating the proprietary rights of companies that produce brand-name drugs.

Trade secrets

The cost of developing a new drug, Gilat explains, has grown dramatically over the last few years, and nowadays reaches several hundreds of millions of dollars and even a billion dollars per drug. One of the reasons for that are technological improvements, which make it possible to reach a higher level of accuracy in toxicity and purity measurements, and concurrently led the Food and Drug Administration (FDA) to introduce more rigorous demands for drug approval.

The Ministry of Health in Israel, like the FDA in the USA, is charged with safeguarding public health. Therefore, any company that develops a new drug must, before it is allowed to market the drug, submit the entire drug file to this agency, including all the data compiled in the clinical trials (trials in humans) and pre-clinical studies (laboratory tests and animal trials).

"The product file is the output of the development process," Gilat explains. "Hundreds of millions of dollars were invested in order to obtain the information in this file, since most of the cost is in clinical trials. This is confidential information, and the incredible investment that was required in order to generate it turns it into a trade secret. The Pharmacists' Ordinance gives the health authorities access to these files, but for one purpose only: to guarantee public health. The Ordinance does not explicitly authorize the government to use the product files for any other purpose."

"Since the file to which the health authorities gain access is a trade secret of the pharmaceutical companies, these companies also have proprietary rights to this file. Their interest in this asset is protected under Basic Law: Human Dignity and Liberty, which stipulates that the authorities may not violate proprietary rights except as provided by explicit legislation, and even then the injury must be proportional."

"At the same time, when a company that produces a generic drug applies for registration of this drug", Gilat says, "this company is not required to perform clinical trials. It is only required to submit a limited set of data that would prove bioequivalence, namely, that the effect produced by the generic product is the same as that produced by the branded original".

The Health Ministry checks whether bioequivalence really exists by comparing the abbreviated file submitted by the generic company to the file of the branded drug. This means that the Health Ministry is using the property of the pharmaceutical company that developed the original drug, in order to approve a generic drug – a purpose that is not permitted by the Ordinance, which only allows the Ministry to use the file in order to guarantee public health.

"The Health Ministry," Gilat says, "is in fact taking private property and using it without permission and against the owners' will, although the property was disclosed to the Ministry as part of a fiduciary relationship and – most importantly – without any explicit law allowing the Ministry to do so."

Protection of Information

Advocate Eran Bareket, an expert in intellectual property law and Gilat's partner, says that by using the drug companies' trade secrets, the Ministry of Health is violating not only the Basic Law and the Pharmacists' Ordinance, but also an explicit undertaking not to divulge or make unfair use of any trade secrets that were disclosed to it in order to gain marketing permits. The State of Israel accepted this undertaking when it joined the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) in 1994.

Article 39 of the Agreement provides that whenever the authorities in a member state require, as a condition of approving the marketing of pharmaceutical or agricultural chemical products (such as new herbicides), that a company submit confidential data whose origination involved a considerable effort, the authorities in this member state are to protect such data against unfair commercial use. In addition, they are to protect this data against disclosure, except where necessary to protect the public, or unless steps are taken to ensure that the data is protected against unfair commercial use.

"Israel signed TRIPS without any reservations," Bareket says. "But international treaties that Israel ratifies do not automatically become part of the binding law here; a law needs to be passed by the Knesset in order to make article 39 of the TRIPS agreement part of the Israeli code; a similar process took place with the Amendment to the Intellectual Property Law (Adaptation to TRIPS)." The Office of the United States Trade Representative (USTR) has repeatedly reprimanded Israel for failing to pass such a law, Bareket adds. According to USTR, this is one of the ways in which TRIPS is violated by Israel.

The western countries, including the U.S. and the members of the European Community, have passed laws designed to give companies that develop drugs or agro-chemical products protection for a limited period, during which no other company can market that product, Bareket notes. For this purpose, they enacted laws protecting information, which apply regardless of whether a drug is patented.

One of the most poignant examples of the need to protect a developer against losing its investment is that of Bristol-Myers Squibb, which developed the ovarian and breast cancer drug, Taxol.

Bristol-Myers Squibb lost its patent protection after generic pharmaceuticals had successfully attacked its patent. They argued that Bristol did not in fact develop the product, since the anti-carcinogenic effect of paclitaxel, the active ingredient in Taxol, was already known. The generic companies based their argument on a provision in Patent Law, according to which medical treatment of humans cannot be protected by patent.

Bristol-Myers Squibb asserted that it had invested US$1 billion in development and clinical trials in order to establish the dosage and treatment schedule, and its investment therefore merits protection. However, this argument was rejected and the patent invalidated.

The Data Protection Law normally affords a company that develops a drug or agro-chemical product five years of protection after FDA marketing approval. This protection is designed to save companies that do not get patent protection or that get it at a later time, from incurring giant losses after applying for FDA approval. For example, if a company obtains FDA approval 20 years less one day after applying for a patent, it will have five years of exclusive distribution rights for that drug, even though the patent expires the next day.

The State of Israel, Bareket concludes, already acknowledged the importance of data protection when it passed the Plant Protection Law. Regulation 19 enacted under this law stipulates that for the first five years after an agro-chemical product is registered, the authorities are not to use the information disclosed to them by the registered owner of the original product in order to issue permits for parallel imports.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions